Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct 26;83(10):1318–1322. doi: 10.1054/bjoc.2000.1438

Low expression of bcl-2 in Brca1-associated breast cancers

P Freneaux 1, D Stoppa-Lyonnet 2, E Mouret 3, M Kambouchner 1, A Nicolas 1, B Zafrani 1, A Vincent-Salomon 1, A Fourquet 4, H Magdelenat 5, X Sastre-Garau 1
PMCID: PMC2408784  PMID: 11044356

Abstract

Little data are available concerning the molecular mechanisms of action of Brca1 and Brca2 in breast oncogenesis. Recent experimental results suggest that Brca1 plays a role in the regulation of apoptosis. In order to determine whether the analysis of human tumours would provide data supporting this hypothesis, we have assessed the expression of the antiapoptotic bcl-2 and of the proapoptotic p53 genes in Brca1- and Brca2-associated breast carcinomas. The levels of expression of these genes were compared to those observed in controls and to the mitotic and the apoptotic indexes. Our series were composed of 16 cases of breast carcinoma in women with a germline Brca1 gene mutation, and of four cases with Brca2 mutation. A group of 39 patients aged under 36 years and for whom the search for Brca1 gene mutations was negative, and a group of 36 cases of sporadic cancers without data on their Brca status were used as controls. Immunohistochemistry was used to detect p53 and bcl-2 gene products. Mitotic and apoptotic indexes were higher in Brca1-associated tumours than in controls. No significant difference in p53 immunostaining was observed between the four groups of patients. In contrast, the rate of bcl-2-positive tumours was lower (31%) in Brca1-carcinomas than in carcinomas without Brca1 mutation (90%) (P< 10–3). A strong Bcl-2 expression was found in the four cases of Brca2-associated carcinomas. No significant correlation was observed between p53 and Bcl-2 immunostainings, either in cases or in controls. The association between Brca1 status and Bcl-2 expression remained significant after adjustment for the oestrogen receptor status. Our study shows that a low expression of bcl-2 characterises most Brca1-associated breast carcinomas, a biological trait which seems not to be shared by Brca2-associated tumours nor to be related to oestrogen receptor and/or p53 status.bcl-2 might thus be one of the target genes involved in the oncogenesis related to Brca1 and its down-regulation may account for the increased apoptosis and the high proliferative rate observed in Brca1-associated carcinomas. © 2000 Cancer Research Campaign

Keywords: Brca1, Brca2, bcl-2, proliferation, apoptosis, breast cancer

Full Text

The Full Text of this article is available as a PDF (443.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnarsson B. A., Jonasson J. G., Björnsdottir I. B., Barkardottir R. B., Egilsson V., Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998 Jan;47(2):121–127. doi: 10.1023/a:1005853022804. [DOI] [PubMed] [Google Scholar]
  2. Ansquer Y., Gautier C., Fourquet A., Asselain B., Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet. 1998 Aug 15;352(9127):541–541. doi: 10.1016/s0140-6736(05)79248-5. [DOI] [PubMed] [Google Scholar]
  3. Armes J. E., Trute L., White D., Southey M. C., Hammet F., Tesoriero A., Hutchins A. M., Dite G. S., McCredie M. R., Giles G. G. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999 Apr 15;59(8):2011–2017. [PubMed] [Google Scholar]
  4. Berardo M. D., Elledge R. M., de Moor C., Clark G. M., Osborne C. K., Allred D. C. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 1;82(7):1296–1302. [PubMed] [Google Scholar]
  5. Bhargava V., Kell D. L., van de Rijn M., Warnke R. A. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol. 1994 Sep;145(3):535–540. [PMC free article] [PubMed] [Google Scholar]
  6. Charpin C., Garcia S., Bouvier C., Devictor B., Andrac L., Lavaut M. N., Allasia C. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas. Br J Cancer. 1997;76(3):340–346. doi: 10.1038/bjc.1997.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crook T., Crossland S., Crompton M. R., Osin P., Gusterson B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1997 Aug 30;350(9078):638–639. doi: 10.1016/S0140-6736(05)63327-2. [DOI] [PubMed] [Google Scholar]
  8. Cummings M. C., Winterford C. M., Walker N. I. Apoptosis. Am J Surg Pathol. 1997 Jan;21(1):88–101. doi: 10.1097/00000478-199701000-00010. [DOI] [PubMed] [Google Scholar]
  9. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gee J. M., Robertson J. F., Ellis I. O., Willsher P., McClelland R. A., Hoyle H. B., Kyme S. R., Finlay P., Blamey R. W., Nicholson R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994 Dec 1;59(5):619–628. doi: 10.1002/ijc.2910590508. [DOI] [PubMed] [Google Scholar]
  11. Gudas J. M., Li T., Nguyen H., Jensen D., Rauscher F. J., 3rd, Cowan K. H. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ. 1996 Jun;7(6):717–723. [PubMed] [Google Scholar]
  12. Hartmann A., Blaszyk H., Kovach J. S., Sommer S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997 Jan;13(1):27–33. doi: 10.1016/s0168-9525(96)10043-3. [DOI] [PubMed] [Google Scholar]
  13. Hellemans P., van Dam P. A., Weyler J., van Oosterom A. T., Buytaert P., Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995 Aug;72(2):354–360. doi: 10.1038/bjc.1995.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huang D. C., O'Reilly L. A., Strasser A., Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997 Aug 1;16(15):4628–4638. doi: 10.1093/emboj/16.15.4628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jacquemier J., Eisinger F., Birnbaum D., Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet. 1995 Jun 10;345(8963):1503–1503. doi: 10.1016/s0140-6736(95)91060-3. [DOI] [PubMed] [Google Scholar]
  16. Joensuu H., Pylkkänen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 1994 Nov;145(5):1191–1198. [PMC free article] [PubMed] [Google Scholar]
  17. Leek R. D., Kaklamanis L., Pezzella F., Gatter K. C., Harris A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer. 1994 Jan;69(1):135–139. doi: 10.1038/bjc.1994.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. O'Reilly L. A., Huang D. C., Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 1996 Dec 16;15(24):6979–6990. [PMC free article] [PubMed] [Google Scholar]
  19. Robson M., Rajan P., Rosen P. P., Gilewski T., Hirschaut Y., Pressman P., Haas B., Norton L., Offit K. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res. 1998 May 1;58(9):1839–1842. [PubMed] [Google Scholar]
  20. Schlichtholz B., Bouchind'homme B., Pagés S., Martin E., Liva S., Magdelenat H., Sastre-Garau X., Stoppa-Lyonnet D., Soussi T. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1998 Aug 22;352(9128):622–622. doi: 10.1016/S0140-6736(05)79576-3. [DOI] [PubMed] [Google Scholar]
  21. Silvestrini R., Benini E., Veneroni S., Daidone M. G., Tomasic G., Squicciarini P., Salvadori B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996 May;14(5):1604–1610. doi: 10.1200/JCO.1996.14.5.1604. [DOI] [PubMed] [Google Scholar]
  22. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  23. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  24. Xu X., Wagner K. U., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C. X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999 May;22(1):37–43. doi: 10.1038/8743. [DOI] [PubMed] [Google Scholar]
  25. Yang X., Lippman M. E. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat. 1999 Mar;54(1):1–10. doi: 10.1023/a:1006189906896. [DOI] [PubMed] [Google Scholar]
  26. van Slooten H. J., van de Vijver M. J., van de Velde C. J., van Dierendonck J. H. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998 Mar;77(5):789–796. doi: 10.1038/bjc.1998.128. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES